MCID: DRG004
MIFTS: 32

Drug-Induced Mental Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Drug-Induced Mental Disorder

MalaCards integrated aliases for Drug-Induced Mental Disorder:

Name: Drug-Induced Mental Disorder 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:1203
ICD9CM 35 292.8 292.89
UMLS 69 C0154325

Summaries for Drug-Induced Mental Disorder

MalaCards based summary : Drug-Induced Mental Disorder is related to paranoid personality disorder and polyneuropathy. An important gene associated with Drug-Induced Mental Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Serotonergic synapse and GPCRs, Other. The drugs Metformin and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include liver and bone, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Related Diseases for Drug-Induced Mental Disorder

Diseases related to Drug-Induced Mental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Related Disease Score Top Affiliating Genes
1 paranoid personality disorder 10.8 HTR1A HTR2A
2 polyneuropathy 10.8 HTR1A HTR2A
3 hodgkin's granuloma 10.8 HTR1A HTR2A
4 teebi kaurah syndrome 10.4 DRD2 HTR2A
5 splenic abscess 10.4 DRD2 HTR2A
6 hyperthyroxinemia 10.4 DRD2 HTR2A
7 kidney cortex necrosis 10.4 NDUFS4 PHB2
8 pompholyx 10.4 DRD2 HTR1A HTR2A
9 abnormal pupillary function 10.4 HTR1A HTR7
10 neuronal ceroid-lipofuscinoses 10.4 LHB PHB2
11 postencephalitic parkinson disease 10.4 DRD2 HTR1A HTR2A
12 cecal benign neoplasm 10.4 DRD2 HTR1A HTR2A
13 bladder flat intraepithelial lesion 10.4 DRD2 HTR1A HTR2A
14 optic disk drusen 10.4 IDH1 IDH2
15 nemaline myopathy 10.3 IDH1 IDH2
16 hepatitis d 10.3 DRD2 HTR1A HTR2A
17 endolymphatic sac tumor 10.3 IDH1 IDH2
18 mixed oligodendroglioma-astrocytoma 10.3 IDH1 IDH2
19 indeterminate leprosy 10.3 HTR2A HTR7
20 congenital disorder of glycosylation, type if 10.3 IDH1 IDH2
21 hepatic angiomyolipoma 10.3 CNR1 HTR2A PINK1
22 hereditary multiple exostoses 10.3 CNR1 DRD2 HTR2A
23 pauci-immune glomerulonephritis with anca 10.3 DRD2 HTR2A NDUFS4
24 aicardi-goutieres syndrome 2 10.3 DRD2 HTR1A HTR2A
25 anca-associated vasculitis 10.3 IDH1 IDH2
26 partial motor epilepsy 10.3 DRD2 HTR1A HTR2A
27 essential pentosuria 10.3 IDH1 IDH2
28 bone osteosarcoma 10.3 IDH1 IDH2
29 breast papillomatosis 10.3 IDH1 IDH2
30 acute pre-b-cell lymphoblastic leukemia 10.2 IDH1 IDH2
31 conjunctival degeneration 10.2 HTR1A HTR2A HTR7
32 early myoclonic encephalopathy 10.2 IDH1 IDH2
33 neurotic disorder 10.2 IDH1 IDH2
34 keratosis 10.2 HTR1A HTR2A HTR7
35 pyromania 10.2 DRD2 HTR2A
36 juxtacortical chondrosarcoma 10.1 IDH1 IDH2
37 chronic conjunctivitis 10.1 CNR1 DRD2 HTR1A HTR2A
38 neurogenic bladder 10.1 HTR2A HTR7
39 schwannoma of jugular foramen 9.9 IDH1 IDH2
40 anosognosia 9.9 DRD2 HTR1A
41 albinism, oculocutaneous, type v 9.8 DRD2 HTR1A HTR2A HTR7
42 autoimmune-related retinopathy and optic neuropathy 9.7 HTR1A HTR2A HTR7
43 hyperimmunoglobulin syndrome 9.6 FOS HTR1A HTR7
44 breast epithelioid hemangioma 9.6 FOS IDH1
45 autoimmune disease of central nervous system 9.6 CNR1 FOS HTR7
46 semantic agnosia 9.6 CNR1 FOS HTR7
47 cervical adenosarcoma 9.6 CNR1 FOS HTR7
48 craniosynostosis, adelaide type 9.5 DRD2 FOS HTR1A HTR2A
49 parkinson disease, late-onset 9.5 CNR1 DRD2 HTR1A HTR2A NDUFS4 PINK1
50 epileptic encephalopathy, early infantile, 45 9.5 CNR1 DRD2 HTR1A HTR2A HTR7

Graphical network of the top 20 diseases related to Drug-Induced Mental Disorder:



Diseases related to Drug-Induced Mental Disorder

Symptoms & Phenotypes for Drug-Induced Mental Disorder

GenomeRNAi Phenotypes related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 ADAMTS2 DRD2 DUSP26 EPHA5 FOS HTR1A

MGI Mouse Phenotypes related to Drug-Induced Mental Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 CNR1 DRD2 FOS HTR1A HTR2A HTR7
2 growth/size/body region MP:0005378 9.96 PINK1 TCOF1 ADAMTS2 CNR1 DRD2 DUSP26
3 integument MP:0010771 9.7 ADAMTS2 CNR1 DRD2 FOS HTR7 NDUFS4
4 nervous system MP:0003631 9.61 CNR1 DRD2 EPHA5 FOS HTR1A HTR7
5 skeleton MP:0005390 9.28 ADAMTS2 CNR1 DRD2 FOS HTR2A IDH1

Drugs & Therapeutics for Drug-Induced Mental Disorder

Drugs for Drug-Induced Mental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
4
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
5
Ziprasidone Approved Phase 4 146939-27-7 60854
6
Lorazepam Approved Phase 4 846-49-1 3958
7
Topiramate Approved Phase 4 97240-79-4 5284627
8
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
9
Clozapine Approved Phase 4 5786-21-0 2818
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Ethanol Approved Phase 4 64-17-5 702
12
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
13
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
14
Memantine Approved, Investigational Phase 4 19982-08-2 4054
15
Asenapine Approved Phase 4,Phase 3 85650-56-2, 65576-45-6 3001386
16
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
20 Quetiapine Fumarate Phase 4,Phase 1 111974-72-2
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Hypoglycemic Agents Phase 4,Phase 3
23 Dopamine Agents Phase 4,Phase 2,Phase 1
24 Dopamine Antagonists Phase 4,Phase 2,Phase 1
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
26
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
27 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Serotonin Antagonists Phase 4,Phase 2,Phase 1
29 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1
35 Anti-Anxiety Agents Phase 4,Phase 1
36 Anticonvulsants Phase 4,Phase 2,Phase 1
37 Anti-Obesity Agents Phase 4
38 GABA Agents Phase 4,Phase 1
39 GABA Modulators Phase 4,Phase 1
40 Hypnotics and Sedatives Phase 4,Phase 1
41 Neuroprotective Agents Phase 4,Phase 2
42 Protective Agents Phase 4,Phase 2
43 Analgesics Phase 4,Phase 1
44 Analgesics, Non-Narcotic Phase 4,Phase 1
45 Antipyretics Phase 4
46 Liver Extracts Phase 4
47 Adrenergic Agents Phase 4,Phase 2,Phase 1
48 Adrenergic Agonists Phase 4,Phase 1
49 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
50 Adrenergic alpha-Agonists Phase 4,Phase 1

Interventional clinical trials:

(show all 45)

id Name Status NCT ID Phase Drugs
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
2 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
3 Antipsychotics and Gene Expression in Soft Tissues Completed NCT01185743 Phase 4 olanzapine;ziprasidone;placebo
4 Characterizing and Predicting Drug Effects on Cognition Completed NCT01889602 Phase 4 Topiramate;Lorazepam
5 Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Completed NCT00845988 Phase 4 aripiprazole
6 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia Completed NCT00269919 Phase 4 Risperidone Long-Acting Injectable (RLAI)
7 Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing Completed NCT00427206 Phase 4 acetaminophen (4g/day);placebo
8 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone
9 Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics Completed NCT00402571 Phase 4 acetaminophen
10 Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia Completed NCT00328367 Phase 4 aripiprazole;placebo
11 The Neural Mechanisms of Anesthesia and Human Consciousness Completed NCT01889004 Phase 4 Dexmedetomidine;Propofol
12 Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease Completed NCT01108029 Phase 4 memantine;placebo
13 The Effect of Paliperidone Palmitate in Schizophrenia Completed NCT01860781 Phase 4 paliperidone palmitate
14 Asenapine in the Treatment of Older Adults With Bipolar Disorder Completed NCT01460290 Phase 4 Asenapine
15 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain Terminated NCT01844700 Phase 4 Ziprasidone;aripiprazole, quetiapine, or risperidone
16 A Study of Olanzapine in Patients With Schizophrenia Completed NCT00970281 Phase 3 Rapid-Acting Intramuscular Olanzapine;Placebo
17 Olanzapine Treatment of Patients With Bipolar I Disorder Completed NCT00510146 Phase 3 Olanzapine;Placebo
18 Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue Completed NCT01794429 Phase 3 Exenatide;Placebo
19 Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125) Completed NCT01142596 Phase 3 Asenapine;Placebo
20 Is MS14 Helpful in Schizophrenia? Unknown status NCT01083381 Phase 2 MS14;Risperidone
21 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2 Levetiracetam
22 An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia Completed NCT00257023 Phase 2 paliperidone
23 A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia Completed NCT01606254 Phase 2 Paliperidone palmitate
24 Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts. Completed NCT01949571 Phase 2 Mirtazapine (REMERON, Schering-Plough-Organon)
25 Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) Terminated NCT00686699 Phase 2 Preladenant;Placebo
26 Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145) Terminated NCT00693472 Phase 2 Preladenant;Placebo;Anticholinergic agents or propanolol;Haloperidol
27 Effect of Affective Content on Drug Induced Amnesia of Episodic Memory Completed NCT00142493 Phase 1 Propofol;Thiopental Sodium;Dexmedetomidine Hydrochloride;Midazolam Hydrochloride;placebo
28 Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1 Completed NCT00218530 Phase 1 Lofexidine
29 BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006) Completed NCT00887601 Phase 1 MK3134;Comparator: Placebo;Donepezil;MK3134
30 Movement Disorders Caused by Antipsychotic Drugs in Older Patients Completed NCT00255879 Phase 1 Quetiapine;Risperidone;Olanzapine
31 Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics Unknown status NCT02366897
32 Vitamin D, SSRIs and the Musculoskeletal System Unknown status NCT01932931
33 Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease Completed NCT00004826 clozapine
34 The Effects of Expectation on Natural and Drug -Induced Rewards Completed NCT01036230
35 Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders Completed NCT00001478
36 Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers Completed NCT01931059 Risperidone
37 Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment Completed NCT00809731
38 Antipsychotic Medication Extended Dosing Study Completed NCT00431574
39 Cognitive Assessment Battery (CAB) Beta Study Completed NCT01290861
40 Switching From Consta® to Sustenna® in Patients With Schizophrenia Completed NCT01698216
41 Risk of Acute Liver Injury in Users of Antimicrobials Completed NCT01434173 Moxifloxacin (Avelox, BAY12-8039);Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
42 Providing "Good Sleep" for ICU Sedation Active, not recruiting NCT01342328 Dexmedetomidine;Propofol
43 Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies Enrolling by invitation NCT02893371 Lithium Carbonate;Lamotrigine;Valproic Acid;Oxcarbazepine;Carbamazepine;Ziprasidone;Risperidone;Quetiapine;Olanzapine;Aripiprazole;Fluoxetine / Olanzapine;Haloperidol;Perphenazine;Clozapine;Asenapine;Lurasidone;Paliperidone;Mirtazapine;Bupropion;Desvenlafaxine;Duloxetine;Venlafaxine;Citalopram;Escitalopram;Fluoxetine;Fluvoxamine;Paroxetine;Sertraline;Vilazodone;Doxepin
44 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions Not yet recruiting NCT03184597
45 Efficiency of Favourite Versus Predetermined Musical Sequence on Gynecology Pre-operative Anxiety Not yet recruiting NCT03226834

Search NIH Clinical Center for Drug-Induced Mental Disorder

Genetic Tests for Drug-Induced Mental Disorder

Anatomical Context for Drug-Induced Mental Disorder

MalaCards organs/tissues related to Drug-Induced Mental Disorder:

39
Liver, Bone

Publications for Drug-Induced Mental Disorder

Variations for Drug-Induced Mental Disorder

Expression for Drug-Induced Mental Disorder

Search GEO for disease gene expression data for Drug-Induced Mental Disorder.

Pathways for Drug-Induced Mental Disorder

GO Terms for Drug-Induced Mental Disorder

Cellular components related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.02 CNR1 DRD2 EPHA5 HTR2A PINK1

Biological processes related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.99 CNR1 DRD2 HTR1A HTR2A HTR7 LHB
2 mitochondrion organization GO:0007005 9.65 IDH2 PHB2 PINK1
3 response to light stimulus GO:0009416 9.59 DRD2 FOS
4 regulation of dopamine secretion GO:0014059 9.58 DRD2 HTR2A
5 behavioral response to cocaine GO:0048148 9.58 DRD2 HTR2A
6 temperature homeostasis GO:0001659 9.57 DRD2 HTR2A
7 smooth muscle contraction GO:0006939 9.56 HTR2A HTR7
8 2-oxoglutarate metabolic process GO:0006103 9.55 IDH1 IDH2
9 vasoconstriction GO:0042310 9.54 HTR1A HTR7
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.52 DRD2 HTR2A
11 regulation of synaptic transmission, GABAergic GO:0032228 9.49 CNR1 DRD2
12 behavior GO:0007610 9.46 HTR1A HTR2A
13 sleep GO:0030431 9.43 FOS HTR2A
14 regulation of behavior GO:0050795 9.4 HTR1A HTR2A
15 regulation of hormone secretion GO:0046883 9.37 HTR1A HTR2A
16 isocitrate metabolic process GO:0006102 9.32 IDH1 IDH2
17 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.26 HTR1A HTR7
18 serotonin receptor signaling pathway GO:0007210 9.16 HTR1A HTR2A
19 negative regulation of dopamine secretion GO:0033602 8.96 CNR1 DRD2
20 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Drug-Induced Mental Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.71 CNR1 DRD2 HTR1A HTR2A
2 drug binding GO:0008144 9.54 CNR1 DRD2 HTR2A
3 neurotransmitter receptor activity GO:0030594 9.33 HTR1A HTR2A HTR7
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.32 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 9.26 IDH1 IDH2
6 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR1A HTR2A HTR7
7 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR7

Sources for Drug-Induced Mental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....